Which of the following is used for treatment of bleeding secondary due to thrombolytic therapy?
**Core Concept**
Thrombolytic therapy involves the administration of drugs that break down blood clots, which can lead to bleeding complications. To manage these bleeding episodes, specific medications are used to control or reverse the effects of thrombolytics.
**Why the Correct Answer is Right**
The correct answer is **Transcarinic acid**. Tranexamic acid works by inhibiting the activation of plasminogen to plasmin, which is the key enzyme responsible for breaking down fibrin clots in the body. By blocking this process, tranexamic acid helps to stabilize clots and reduce bleeding. This mechanism is particularly useful in the context of thrombolytic therapy, where bleeding complications can be severe.
**Why Each Wrong Option is Incorrect**
**Option A:** **Aminocaproic acid** is also an antifibrinolytic agent, but it works by inhibiting plasminogen activation. While it is used to treat bleeding complications, it is not the first-line treatment for bleeding due to thrombolytic therapy.
**Option B:** **Fresh frozen plasma (FFP)** is used to replace clotting factors in patients with bleeding disorders, but it is not specifically used to treat bleeding secondary to thrombolytic therapy.
**Option C:** **Platelet transfusion** is used to increase platelet counts in patients with thrombocytopenia, but it does not directly address the issue of bleeding due to thrombolytic therapy.
**Clinical Pearl / High-Yield Fact**
In the context of thrombolytic therapy, it's essential to remember that tranexamic acid is the preferred treatment for bleeding complications due to its ability to inhibit plasminogen activation and stabilize clots.
**Correct Answer: C. Tranexamic acid**